Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drug
Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...
Hosted on MSN2d
Dimerix posts modest gain as first Japanese payment for DMX-200 lands
Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...
TipRanks on MSN3d
Dimerix Limited Announces Quotation of New Securities on ASX
Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...
Health Check: More, please! When record results are not good enough for expectant investors
Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...
Petra Capital Reaffirms Their Buy Rating on Dimerix Limited (DXB)
In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...
stockhead15d
Middle East healthcare expansion opens doors for ASX stocks
Taiba also has a right to negotiate a licence to develop and commercialise DMX-200 in any additional indications in the licensed territories that Dimerix may achieve for DMX-200. The minimum term for ...
The Australian Financial Review27d
Dimerix Limited
Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.